Marah Short, associate director of the Center for Health and Biosciences at Rice University’s Baker Institute for Public Policy, started out doing research for cancer care policies, but since the ACA, her focus has predominately been on studying the effects of the ACA and how health care can be managed more effectively.

Dr. Anthony LoSasso, professor of health policy and administration at the University of Illinois at Chicago, has been focusing on health insurance issues involving ACA expansion, insurance programs and benefit design.

A recent update on questions regarding the Medicare Electronic Health Record (EHR) Incentive Program has been released by CMS.

The FDA recently approved Afinitor, a new drug from Novartis that is designed to treat progressive, nonfunctional gastrointestinal as well as lung neuroendocrine tumors.

The U.S. Food and Drug Administration has approved Pfizer's XELJANZ XR as a daily treatment option for moderate to severe rheumatoid arthritis (RA).

AstraZeneca and MedImmune, the worldwide biologics research and development branch, recently released the top-line results from their tremelimumab monotherapy trial involving mesothelioma.

The U.S. Food and Drug Administration (FDA) recently stated that there is now a total of $2 million in research grants available to finance natural history studies of rare diseases.

Aetna is a large health benefits provider, serving over 1.6 million individuals throughout Pennsylvania, and now, thanks to a new agreement between a local hospital, patients can receive quality care more conveniently.

Dan Durham, executive vice president of Health Policy at Biotechnology Innovation Organization (BIO), recently made a statement about the White House decision to advance the Precision Medicine Initiative.

Tissue plasminogen activators have been used for more than 20 years to break up blood clots and help stroke patients avoid brain damage.

Following an 89-4 Senate vote, Robert Califf has been confirmed as the new commissioner of the U.S. Food and Drug Administration (FDA), after serving the organization as deputy commissioner of medicine and tobacco.

Rare Disease Day was held Feb. 29, a day set aside to raise awareness about the world's approximately 7,000 conditions that are classified as rare diseases.

By presidential proclamation, March is National Colorectal Cancer Awareness Month -- a time set aside both to honor survivors and to promote awareness and the need for ongoing research.

The National Institute of Diabetes and Digestive Kidney Diseases, an arm of the National Institutes of Health, has named Christopher Lynch director of its Office of Nutrition Research and chief of its Nutrition Research Branch.

Researchers from the National Institutes of Health (NIH) have uncovered evidence that suggests pregnant women living with asthma who are exposed to high levels of traffic-related air pollution may be at an increased risk of having premature babies.

According to the Capital Research Center, Obamacare is pitting various sectors of the medical industry against each other by creating a culture in which each sector is attempting to shift policies in its favor at the expense of other sectors and consumers.

Data pooled from separate studies show that Ofev slows idiopathic pulmonary fibrosis (IPF) disease progression and reduces the risk of acute exacerbations.

Researchers from French pharmaceutical company Sanofi recently unveiled results from their phase 1/2 clinical study, dubbed NEO1, which assessed the effectiveness of neoGAA, a potential treatment for patients with late-onset Pompe disease.

Researchers from all over the world are working on initiatives to find new treatments for autoimmune disorders. To help achieve that goal, Opexa Therapeutics Inc. has revamped the ways its resources will be used going forward.

Multiple AbbVie team members have been serving as presenters at the 74th Annual Meeting of the American Academy of Dermatology, which began March 4 in Washington, D.C., and will wrap up on March 8.